Cinclus Pharma: PCABs off to a strong start since launch in the US
In its first year on the market, PCABs have shown strong uptake as highlighted by Phathom's FY'24 results on vonoprazan (1st-gen PCAB), which exceeded market expectations coming in at USD29.7m (+81% QoQ, +19% vs. CSS) — despite the positives the stock remained under pressure after open likely due t
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.